In breast cancer, miR-221 is the target of GAS5 [21], and GAS5 regulates DKK2 expression by competitively binding miR-221-3p, inhibiting the activation of Wnt / β-Catenin pathway, enhancing the anti-tumor effect of adriamycin [22]. Here, GAS5 is linked to breast cancer.